Home
Clinical Resources Search
PQI: Pacritinib (Vonjo®) in Cytopenic Myelofibrosis

Pacritinib (Vonjo®) in Cytopenic Myelofibrosis

Download PQI pdf

Last Updated: May 31, 2024

By: Sarah Rockwell, PharmD, BCOP

About this PQI

The purpose of this PQI is to discuss clinical considerations and adverse effect management surrounding the use of pacritinib (Vonjo®) in myelofibrosis (MF) and thrombocytopenia.

More About This PQI

PQI in Action Articles:

PACRITINIB-In-CYTOPENIC-MYELOFIBROSIS-NCODA-PQI-IN-ACTION- pdf

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Frequently Searched

Supported by

Pacritinib (Vonjo®) in Cytopenic Myelofibrosis

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal

PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease

PQI: Gedatolisib Combination Therapy for Locally Advanced or Metastatic Breast Cancer

PQI: Relacorilant (LIFYORLI) and Albumin-Bound Paclitaxel (Nab-Paclitaxel) for Platinum-Resistant Ovarian Cancer

PQI in Action: Inavolisib (Itovebi) Patient Management

PQI in Action: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI in Action: Capivasertib (Truqap) Patient Management

PQI in Action: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

S11 E9: Keep Saying Yes: Living, Advocating, and Finding Purpose with Cancer

S11 E10: Fungi, Facts, and Cancer Care: Exploring Medicinal Mushrooms

S11 E8: The Future of Oncology

S11 E7: Your Health Story in One Place

Toolkit: Simplify CLL Tracking in Oncology Practices

Toolkit: Optimize CLL Care in Epic

Treatment Support Kit: Elranatamab

Treatment Support Kit: Bispecific (T-Cell Engager)

Treatment Support Kit: Zanidatamab-hrii

Treatment Support Kit: Avutometinib and Defactinib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

S7 Ep 8: Sickle Cell Disease Insights

PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease

Pacritinib

Momelotinib

Ruxolitinib

Ruxolitinib

PQI in Action: Ropeginterferon alfa-2b-njft (BESREMi®) Use in Polycythemia Vera

Pacritinib

Treatment Support Kit: Pacritinib

PQI in Action: Pacritinib (Vonjo®) In Cytopenic Myelofibrosis

Pacritinib

Treatment Support Kit: Pacritinib

PQI in Action: Pacritinib (Vonjo®) In Cytopenic Myelofibrosis

PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal

PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease

Rusfertide (Mimrylo)

Lirafugratinib (Lyrfigtu)